APR 07, 2020 8:19 AM PDT

Second COVID-19 Vaccine Enters Human Trials

WRITTEN BY: Carmen Leitch

Yesterday, Inovio Pharmaceuticals, Inc. announced that it will begin human trials on a potential vaccine for COVID-19. The US Food and Drug Administration accepted its investigational drug application for the candidate vaccine, now called INO-4800, and the company will start injecting healthy volunteers in a Phase I trial as soon as this week.

Preclinical data obtained using various animal models have shown that the vaccine can initiate an immune response. Now, the company has to demonstrate that it triggers an immune response in people as well and that it is safe.

The Phase 1 trial will be enrolling around 40 healthy participants at one of two sites: the Perelman School of Medicine at the University of Pennsylvania in Philadelphia or the Center for Pharmaceutical Research in Kansas City, Missouri. Every volunteer is slated to receive two doses of the vaccine, one four weeks after the other. The company expects the results from the trial in late summer.

"We anticipate rapid enrollment of this initial study," said the Principal Investigator of the study Pablo Tebas, MD, an infectious disease specialist and professor of Medicine at the Hospital of the University of Pennsylvania. "There has been tremendous interest in this vaccine among people who want to do what they can to help protect the greater public from this pandemic as soon as possible."

Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. / Credit: NIAID

Their vaccine uses a small piece of DNA that is injected into the body (and is supposed to initiate an immune response). Like other vaccines, priming the immune system in this way gives the body a 'memory' of an infection so that if it does encounter the pathogen, it already has antibodies in place to fight it. DNA vaccines are used in veterinary medicine but have not yet been used in humans.

Inovio is supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill and Melinda Gates Foundation. Bill Gates has said in a recent interview that his foundation is planning to pick seven top COVID-19 vaccine candidates and generate the infrastructure to manufacture all of them. Not every one will be a winner, he said two at most might make it to market, but this will rapidly accelerate the process by building a factory as the vaccine is being developed, instead of waiting until it's already been created to start construction.

If the trials produce good results, Inovio claims it can have up to one million vaccine doses ready for around the end of the year, which could be used in more trials or as emergencies required. It would take a few more months to have the vaccine ready for a wider rollout.

"This is a significant step forward in the global fight against COVID-19," said the President and CEO of Inovio,  Dr. J. Joseph Kim. "Without a new safe and effective vaccine, the COVID-19 pandemic is likely to continue to threaten lives and livelihoods. It also demonstrates the power of our DNA medicines platform to rapidly develop and advance a vaccine for COVID-19 into Phase 1 clinical testing. Our dedicated team of staff, partners and funders have been mobilized since the genetic sequence of the virus became available in early January and continues to work around the clock to ensure that we are rapidly advancing INO-4800 through this Phase 1 study towards planned efficacy trials."

Inovio also already has a little experience in this field. The company has previously completed a successful clinical trial that tested a vaccine for the coronavirus that causes MERS.

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 24, 2020
Microbiology
Genetic Variations Can Affect the Gut Microbiome
JUN 24, 2020
Genetic Variations Can Affect the Gut Microbiome
The small variations in the human genome aren't the only thing that make us unique. We also each carry communities of mi ...
JUL 05, 2020
Microbiology
Stimulating Antibiotic Production in Bacteria
JUL 05, 2020
Stimulating Antibiotic Production in Bacteria
The microorganisms of the world have to compete for survival, and they sometimes do battle with one another. Some use an ...
JUL 23, 2020
Genetics & Genomics
A Human Protein Can Mutate SARS-CoV-2, But It Can Change Back
JUL 23, 2020
A Human Protein Can Mutate SARS-CoV-2, But It Can Change Back
One way the human body can try to fight the coronavirus is by mutating it; these mutations seem to disrupt it. But the v ...
JUL 24, 2020
Microbiology
Ticks Carrying Heartland Virus Found in Illinois
JUL 24, 2020
Ticks Carrying Heartland Virus Found in Illinois
In two counties in Illinois, a pathogen continues its emergence. Researchers have found that Lone Star ticks there are c ...
AUG 11, 2020
Cell & Molecular Biology
New Microscopy Tools Reveal More About the Role of Actin
AUG 11, 2020
New Microscopy Tools Reveal More About the Role of Actin
Cells rely on a network of tiny filaments to give them form and support their structure. One crucial filament is a prote ...
SEP 10, 2020
Clinical & Molecular DX
Microscope to Diagnose River Blindness Is a Winner
SEP 10, 2020
Microscope to Diagnose River Blindness Is a Winner
  A team of innovators from Stanford University has invented the Onchoscope: a low-cost, customizable microscope fo ...
Loading Comments...